Quality of Life of Persons Suffering From Schizophrenia, Psoriasis and Physical Disabilities

Palijan, Tija Žarković; Kovačević, Dražen; Vlastelica, Mirela; Dadić-Hero, Elizabeta; Sarilar, Marijana

doi:10.24869/psyd.2017.60

Cited by 15 publications

(4 citation statements)

References 26 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have reported that psoriasis strongly influences the global QoL of psoriasis individuals (Langley et al, 2005;Palijan et al, 2017;Salman et al, 2018). Up until this moment, this is the first study that addresses oral health-related quality of life in individuals with psoriasis particularly directed at the presence of oral lesions.…”

Section: Discussionmentioning

confidence: 91%

Impact of oral lesions on the quality of life of psoriatic individuals: A case–control study

et al. 2020

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease, characterized by dermis and epidermis inflammation and by itching, scaly red spots, papules, and plaques (Zargari, 2006). It has a prevalence of 2%-4% in the general population, leading to significant impacts on physical and emotional health related to quality of life (QoL) (Boehncke & Schön, 2015;Christophers, 2001).Contributing factors as environmental causative agents of the disease include trauma, staphilocossis sp, streptococcis sp, HIV infections, candida species, medications, stress, smoking, and alcohol

show abstract

Section: Discussionmentioning

confidence: 91%

Impact of oral lesions on the quality of life of psoriatic individuals: A case–control study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This result is in line with previous work. 34,35 The impacts included work life, social activities, relationships with family and friends, and romantic relationships. Social impacts may in part owe to embarrassment participants indicating experiencing over anxiety, sexual dysfunction, trouble concentrating, and weight gain; these side effects again partially overlapping with those frequently cited as bothersome.…”

Section: Discussionmentioning

confidence: 99%

<p>Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey</p>

Doane¹,

Sajatovic²,

Weiden³

et al. 2020

PPA

View full text Add to dashboard Cite

Background This survey examined the experiences of people living with schizophrenia who have used oral antipsychotics (APs). Methods Adults with self-reported physician-diagnosed schizophrenia (N=200), who were members of an online research participation panel and reported taking one or more oral APs within the last year, completed a cross-sectional online survey that focused on direct report of their experiences regarding APs (eg, symptoms, side effects, adherence). Descriptive analyses were conducted for the total survey sample and for subgroups defined a priori by experience with specific, prevalent side effects. Results The mean age of the sample was 41.9 (SD=11.0) years, 50% of participants were female, and 32% were nonwhite. Overall ratings were positive for medication effectiveness and convenience but negative for side effects. While most participants reported that APs improved schizophrenia symptoms (92%), 27% reported APs as having done “more harm than good.” Almost all participants (98%) reported experiencing side effects of APs, with the most common being anxiety (88%), feeling drowsy/tired (86%), and trouble concentrating (85%). Side effects frequently cited as either “extremely” or “very” bothersome were weight gain (56%), sexual dysfunction (55%), and trouble concentrating (54%). Over 80% reported that side effects had negatively impacted their work and social functioning (eg, social activities or family/romantic relationships). Since initiating treatment, 56% of respondents had stopped taking APs at some point (65% of these due to side effects). Side effects commonly reported as having led to stopping AP treatment were “feeling like a ‘zombie’” (22%), feeling drowsy/tired (21%), and weight gain (20%). Conclusion Most participants reported improvements in schizophrenia symptoms associated with the use of APs. However, most participants also reported experiencing numerous bothersome side effects that negatively impacted their work, social functioning, and treatment adherence. Results highlight the unmet need for new APs with favorable benefit-risk profiles.

show abstract

“…[2][3][4] The prevalence of psoriasis in China has increased from 0.12% to 0.47% during the past two decades. 5,6 Psoriasis has a significant negative impact on health-related quality of life, [7][8][9][10] and nonadherence to treatment is a pivotal risk factor for aggravation of psoriasis conditions. 11 The current study aimed to investigate the association of nonadherence to treatment with the patient-reported outcomes of psoriasis, including the aggravation of psoriasis conditions, stress, anxiety, and depression during the period of COVID-19 epidemic.…”

Section: Introductionmentioning

confidence: 99%

<p>Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis During the COVID-19 Epidemic: A Web-Based Survey</p>

Wang¹,

Luo²,

Lv³

et al. 2020

PPA

View full text Add to dashboard Cite

Purpose The COVID-19 epidemic has caused difficulties in continuous treatment for patients with chronic diseases and resulted in nonadherence to treatment and adverse health outcomes. This study aimed to investigate the associations of nonadherence to treatment with patient-reported outcomes of psoriasis during the COVID-2019 epidemic. Methods A cross-sectional study among Chinese patients with psoriasis was conducted through a web-based questionnaire survey during 25 Feb 2020 and 6 Mar 2020. Demographic and clinical data, nonadherence to treatment, and patient-reported outcomes were collected. The outcomes included deterioration of the disease condition, perceived stress, and symptoms of anxiety and depression. Logistic regression was used to investigate the associations. Results A total of 926 questionnaires were collected. A total of 634 (68.5%) reported nonadherence to treatment, and worse adherence was found among patients receiving systemic treatment (adjusted odds ratio [AOR]: 2.67; 95% CI: 1.40–5.10) and topical treatment (AOR: 4.51; 95% CI: 2.66–7.65) compared to biological treatment. Nonadherence to treatment (less than two weeks and more than two weeks) was significantly associated with deterioration of psoriasis (aOR: 2.83 to 5.25), perceived stress (AOR: 1.86 to 1.57), and symptoms of anxiety (AOR: 1.42 to 1.57) and depression (AORs: 1.78). Subgroup analysis by treatment showed consistent results in general. Conclusion Nonadherence to treatment was associated with the aggravation of psoriasis conditions, perceived stress, and symptoms of anxiety and depression.

show abstract

Quality of Life of Persons Suffering From Schizophrenia, Psoriasis and Physical Disabilities

Cited by 15 publications

References 26 publications

Impact of oral lesions on the quality of life of psoriatic individuals: A case–control study

Impact of oral lesions on the quality of life of psoriatic individuals: A case–control study

<p>Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey</p>

<p>Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis During the COVID-19 Epidemic: A Web-Based Survey</p>

Contact Info

Product

Resources

About